Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer

BACKGROUND: Bevacizumab plus taxane chemotherapy improves progression-free survival (PFS) versus taxane monotherapy in the first-line treatment of HER2-negative metastatic breast cancer (MBC) and appears promising in the second-line setting. This retrospective analysis evaluated the efficacy and saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Redondo, Andrés, Martínez, Virginia, Zamora, Pilar, Castelo, Beatriz, Pinto, Alvaro, Cruz, Patricia, Higuera, Oliver, Mendiola, Marta, Hardisson, David, Espinosa, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251573/
https://www.ncbi.nlm.nih.gov/pubmed/25473300
http://dx.doi.org/10.2147/OTT.S70654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251573/
https://www.ncbi.nlm.nih.gov/pubmed/25473300
http://dx.doi.org/10.2147/OTT.S70654

Ejemplares similares